


## QDENGGA (TAK-003)

July 21, 2026 • vajiramandravi.com



### QDENGGA (TAK-003) Latest News

The Drug Controller General of India (DCGI) recently granted market authorisation to Takeda Biopharmaceuticals India's QDENGGA (TAK-003), making it the first dengue vaccine to be approved in the country.

### About QDENGGA (TAK-003)

- It is a **dengue vaccine** developed by the **Japanese pharmaceutical company Takeda**.
- It is the **first dengue vaccine** to be **approved in India**.
- The vaccine has been **approved** for the prevention of dengue in **individuals aged four to 60**.
- QDENGGA is a **live-attenuated (weakened) tetravalent vaccine** designed to provide **protection against all four dengue virus serotypes (DENV-1 to DENV-4)**.
- It is administered as a **two-dose regimen**, with doses given **three months apart**.
- The vaccine can be **administered irrespective** of whether an **individual has had a previous dengue infection** and **does not require pre-vaccination screening**.

- The vaccine has already been **approved in more than 40 countries**, including the European Union, the United Kingdom, Brazil, Indonesia, and Argentina.

## What is Dengue?

- **Dengue** disease is a **mosquito-borne tropical disease** caused by the **dengue virus**, leading to mild, **flu-like symptoms** in most people.
- However, a small number of patients develop **severe disease**, with potentially **fatal bleeding and organ damage**.
- It poses a significant **global public health threat**, with prevalence in over **125 countries**.
- **India** accounts for nearly **one-third** of the global dengue burden.

Source: **TH**

---

Source: <https://vajiramandravi.com/current-affairs/qdenga-tak-003/>

© Vajiram & Ravi. For personal use only.